NCT07717879
A Study to Assess the Efficacy and Safety of Solriamfetol in Children With ADHD
Recruiting
PHASE3Ages 6–11InterventionalTreatmentAxsome Therapeutics, Inc.
~468 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:Solriamfetol Dose ASolriamfetol Dose BPlacebo
At a glance
Recruiting sites
9 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
ADHD-RS-5 Total Score, Change from Baseline to Week 6
Measured over 6 weeks
Conditions
Where it's being run
9 sites across 6 statesFlorida4
Alabama1
Arkansas1
Kentucky1
Tennessee1
Texas1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male or female, aged 6 to \<12 years.
Primary diagnosis of ADHD according to DSM-5 criteria.
Has parents/legal guardians provide written informed consent and has child provide written informed assent to participate in the study before the conduct of any study procedures.
Exclusion
Unable to comply with study procedures.
Medically inappropriate for study participation in the opinion of the investigator.
What this trial measures
- ADHD-RS-5 Total Score, Change from Baseline to Week 66 weeks
Attention Deficit/ Hyperactivity Disorder Rating Scale-5, Interview with Informant, Child Version (ADHD-RS-5)